A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
Condition: SARS-CoV-2 Interventions: Biological: mRNA-1273; Biological: Placebo Sponsors: ModernaTX, Inc.; Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | COVID-19 | Infectious Diseases | Research | SARS | Study | Vaccines